謝咪雪
查看科室更多醫(yī)生
出診信息
注：出診時間如有變化,，以當日掛號為準| 門診時間 | 門診地點 |
|---|---|
| 星期 日 (上午) | 慶春院區(qū) |
個人簡介
醫(yī)學博士，碩士生導師,，特聘研究員,，從事血液腫瘤的基礎和臨床轉(zhuǎn)化研究,，承擔國家自然科學基金等多項課題,，以第一/通訊作者在血液學TOP期刊Leukemia,、Nature子刊發(fā)表SCI論文20余篇，獲2022年全國“35 under 35”優(yōu)秀青年腫瘤醫(yī)生獎,。
專業(yè)擅長
白血病,、淋巴瘤、骨髓瘤,、貧血,、各類白細胞減少、血小板減少等診治,，尤其在血液病惡性腫瘤領域有豐富的診治經(jīng)驗,。
研究方向
致力于急性淋巴細胞白血病耐藥機制和臨床轉(zhuǎn)化性研究。
成果獎項：（近五年主要成果及獎勵情況）
(1) Xie M, Yang A, Ma J, Wu M, Xu H, Wu K, Jin Y, Xie Y. Akt2 mediates glucocorticoid resistance in lymphoid malignancies through FoxO3a/Bim axis and serves as a direct target for resistance reversal. Cell Death Dis, 2019, 9: 1013.
(2) Yang C, Xie M, Zhang K, Liu H, Liang A, Young KH, Qian W. Risk of HBV reactivation post CD19-CAR-T cell therapy in DLBCL patients with concomitant chronic HBV infection. Leukemia, 2020, 34: 3055-3059.
(3) Xie M, Wang L, Jiang Q, Luo X, Zhao X, Li X, Jin J, Ye X, Zhao K. Significance of initial, interim and end-of-therapy (18)F-FDG PET/CT for predicting transformation risk in follicular lymphoma. Cancer Cell Int, 2021, 21: 394.
(4) Xie M, Huang X, Ye X, Qian W. Prognostic and clinicopathological significance of PD-1/PD-L1 expression in the tumor microenvironment and neoplastic cells for lymphoma. Int Immunopharmacol, 2019, 77: 105999.
(5) Xie M, Jiang Q, Zhao S, Zhao J, Ye X, Qian W. Prognostic value of tissue- infiltrating immune cells in tumor microenvironment of follicular lymphoma: A meta-analysis. Int Immunopharmacol, 2020, 85: 106684.
(6) Lei W, Xie M, Jiang Q, Xu N, Li P, Liang A, Young KH, Qian W. Treatment-Related Adverse Events of Chimeric Antigen Receptor T-Cell (CAR T) in Clinical Trials: A Systematic Review and Meta-Analysis. Cancers (Basel), 2021, 13: 3912.
